OBJECTIVE: The authors assessed the association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and scores on the phobic anxiety scale of the Crown-Crisp Experimental Index. METHOD: A total of 1,234 women completed the Crown-Crisp Experimental Index phobic anxiety scale and were genotyped for the COMT polymorphism. The authors used unconditional logistic regression to compute odds ratios and 95% confidence intervals (CIs) to evaluate the association between the COMT genotype and phobic anxiety. RESULTS: The mean scores for the three genotypes were statistically significantly different. Compared to the COMT Met/Met genotype, the age-adjusted odds ratio for scoring >/=6 compared to scoring 0 or 1 were 1.15 (95% CI=0.71-1.85) and 1.99 (95% CI=1.17-3.40) for the COMT Val/Met and COMT Val/Val genotypes, respectively; a significant gene dosage effect was observed. CONCLUSIONS: Our results suggest that the functional COMT polymorphism is associated with the development of phobic anxiety.
OBJECTIVE: The authors assessed the association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and scores on the phobic anxiety scale of the Crown-Crisp Experimental Index. METHOD: A total of 1,234 women completed the Crown-Crisp Experimental Index phobic anxiety scale and were genotyped for the COMT polymorphism. The authors used unconditional logistic regression to compute odds ratios and 95% confidence intervals (CIs) to evaluate the association between the COMT genotype and phobic anxiety. RESULTS: The mean scores for the three genotypes were statistically significantly different. Compared to the COMT Met/Met genotype, the age-adjusted odds ratio for scoring >/=6 compared to scoring 0 or 1 were 1.15 (95% CI=0.71-1.85) and 1.99 (95% CI=1.17-3.40) for the COMT Val/Met and COMT Val/Val genotypes, respectively; a significant gene dosage effect was observed. CONCLUSIONS: Our results suggest that the functional COMT polymorphism is associated with the development of phobic anxiety.
Authors: William Maixner; Luda Diatchenko; Ronald Dubner; Roger B Fillingim; Joel D Greenspan; Charles Knott; Richard Ohrbach; Bruce Weir; Gary D Slade Journal: J Pain Date: 2011-11 Impact factor: 5.820
Authors: Michael J Sulik; Nancy Eisenberg; Tracy L Spinrad; Kathryn Lemery-Chalfant; Gregory Swann; Kassondra M Silva; Mark Reiser; Daryn A Stover; Brian C Verrelli Journal: Dev Psychopathol Date: 2014-08-27
Authors: Haroon I Sheikh; Katie R Kryski; Heather J Smith; Lea R Dougherty; Daniel N Klein; Sara J Bufferd; Shiva M Singh; Elizabeth P Hayden Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-03-08 Impact factor: 3.568
Authors: John M Hettema; Seon-Sook An; Jozsef Bukszar; Edwin J C G van den Oord; Michael C Neale; Kenneth S Kendler; Xiangning Chen Journal: Biol Psychiatry Date: 2008-04-23 Impact factor: 13.382
Authors: Karin F Hoth; Robert H Paul; Leanne M Williams; Carol Dobson-Stone; Elizabeth Todd; Peter R Schofield; John Gunstad; Ronald A Cohen; Evian Gordon Journal: Neuropsychiatr Dis Treat Date: 2006-06 Impact factor: 2.570
Authors: Andrea G Nackley; Svetlana A Shabalina; Jason E Lambert; Mathew S Conrad; Dustin G Gibson; Alexey N Spiridonov; Sarah K Satterfield; Luda Diatchenko Journal: PLoS One Date: 2009-04-13 Impact factor: 3.240